| XIAP’s Profile in Human Cancer H Tu, M Costa Biomolecules 10 (11), 1493, 2020 | 61 | 2020 |
| Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells N Zhang, X Hua, H Tu, J Li, Z Zhang, C Max Cancer Letters 520, 400-408, 2021 | 34 | 2021 |
| Loss of MEG3 and upregulation of miR-145 play an important role in the invasion and migration of Cr (VI)-transformed cells Z Zhang, J Li, B Yan, H Tu, C Huang, M Costa Heliyon 8 (8), 2022 | 4 | 2022 |
| Isorhapontigenin (ISO) inhibits malignant cell transformation, migration, and invasion through MEG3/NEDD9 signaling in Cr (VI)-transformed cells S Shi, J Li, Z Zhang, H Tu, C Max Toxicology and Applied Pharmacology 476, 116661, 2023 | 2 | 2023 |
| Loss of MEG3 contributes to the enhanced migration and invasion in arsenic-induced carcinogenesis through NQO1/FSCN1 pathway H Tu, Z Zhang, J Li, S Shi, M Costa American Journal of Cancer Research 13 (6), 2307, 2023 | 2 | 2023 |
| Inhibition of isorhapontigenin on migration and invasion of bladder cancer cells depends on Sestrin 2 and Beclin 1 Z Zhang, J Li, H Tu, M Costa Cancer Research 82 (12_Supplement), 5993-5993, 2022 | 1 | 2022 |
| Abstract LB049: Isoharpontigenin inhibits migration and invasion of lung cancer cells through MEG3/EGFR pathway S Shi, Z Zhang, J Li, H Tu, M Costa Cancer Research 84 (7_Supplement), LB049-LB049, 2024 | | 2024 |
